O-Bio

Orchestra BioMed is a biomedical innovation company focused on developing and commercializing therapeutic products addressing significant unmet clinical needs. The firm primarily develops late-stage medical technologies, such as Atrioventricular Interval Modulation (AVIM) Therapy for hypertension and the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for artery disease, leveraging a partnership-enabled business model with leading medical device companies.

David Hochman founded Orchestra BioMed, serving as Chairman and Chief Executive Officer since May 2018. His extensive background in healthcare entrepreneurship, venture capital, and investment banking informed the company's unique approach. The foundational insight centered on accelerating high-impact medical innovations to patients through strategic, risk-reward sharing collaborations rather than traditional full-scale development.

Orchestra BioMed's product candidates are designed for patients suffering from chronic hypertension and atherosclerotic artery disease. The company's overarching vision is to bring transformative medical innovations to life, aiming to enhance patient outcomes globally by ensuring efficient development and broad commercialization of its therapeutic solutions through its collaborative model.